GlobeNewsWire
14 Jul 2026, 00:35 UTC · 10w ago
Verdict
Headline takes no side. We score MSB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Mesoblast has reached its target of treating at least 300 patients in the pivotal Phase 3 trial for rexlemestrocel-L targeting chronic low back pain.
More positive than 92% of claims this week
The chronic low back pain indication is estimated to have a potential peak year revenue exceeding US$10 billion with single-digit market penetration.
So whatThis establishes the massive commercial scale and potential for a 'blockbuster' valuation if the drug is approved.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Rexlemestrocel-L has received RMAT designation from the FDA, making it eligible for priority review upon filing a Biologics License Application.
More positive than 63% of claims this week
Top-line results for the Phase 3 trial are expected in mid-CY2027.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company achieved its target enrollment for a pivotal Phase 3 trial for a potentially blockbuster treatment.
More positive than 86% of ticker scores this week
The company achieved its target enrollment for a pivotal Phase 3 trial for a potentially blockbuster treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
−19.8%
Price is moving against the score
$20.17 vs $25.16 close before publication (Jul 13) · not market-adjusted
MSB chart →
